[go: up one dir, main page]

AU2002241611A1 - Orally-bioavailable formulations of fentanyl and congeners thereof - Google Patents

Orally-bioavailable formulations of fentanyl and congeners thereof

Info

Publication number
AU2002241611A1
AU2002241611A1 AU2002241611A AU4161102A AU2002241611A1 AU 2002241611 A1 AU2002241611 A1 AU 2002241611A1 AU 2002241611 A AU2002241611 A AU 2002241611A AU 4161102 A AU4161102 A AU 4161102A AU 2002241611 A1 AU2002241611 A1 AU 2002241611A1
Authority
AU
Australia
Prior art keywords
congeners
fentanyl
orally
bioavailable formulations
bioavailable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002241611A
Other languages
English (en)
Inventor
Liming Shao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU2002241611A1 publication Critical patent/AU2002241611A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2002241611A 2000-12-04 2001-10-26 Orally-bioavailable formulations of fentanyl and congeners thereof Abandoned AU2002241611A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25114400P 2000-12-04 2000-12-04
US60/251,144 2000-12-04
PCT/US2001/047651 WO2002045713A2 (fr) 2000-12-04 2001-10-26 Formulations a biodisponibilite orale de fentanyl et de congeneres

Publications (1)

Publication Number Publication Date
AU2002241611A1 true AU2002241611A1 (en) 2002-06-18

Family

ID=22950663

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002241611A Abandoned AU2002241611A1 (en) 2000-12-04 2001-10-26 Orally-bioavailable formulations of fentanyl and congeners thereof

Country Status (3)

Country Link
US (1) US20020160991A1 (fr)
AU (1) AU2002241611A1 (fr)
WO (1) WO2002045713A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2005065319A2 (fr) * 2003-12-31 2005-07-21 Cima Labs Inc. Forme galenique de fentanyl generalement lineaire effervescente et orale et ses procedes d'administration
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
CA2549642C (fr) * 2003-12-31 2012-10-30 Cima Labs Inc. Formes galeniques d'opiates orales effervescentes et procedes d'administration d'opiates
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
RU2432950C2 (ru) 2006-01-25 2011-11-10 Инсис Терапьютикс Инк. Подъязычный спрей на основе фентанила
PT103884A (pt) * 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
NO2180844T3 (fr) * 2007-08-02 2018-07-21
EP2039360A1 (fr) * 2007-09-19 2009-03-25 Euro-Celtique S.A. Administration directe non invasive d'opioïdes au système nerveux central
US20140179615A1 (en) * 2012-07-12 2014-06-26 Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. Glutathione and Acetaminophen Composition and Preparation Method Thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
US5759573A (en) * 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5451408A (en) * 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
US6635661B2 (en) * 2000-05-25 2003-10-21 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
US6740639B1 (en) * 2000-03-29 2004-05-25 Council Of Scientific & Industrial Research Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment

Also Published As

Publication number Publication date
US20020160991A1 (en) 2002-10-31
WO2002045713A2 (fr) 2002-06-13
WO2002045713A3 (fr) 2003-04-03

Similar Documents

Publication Publication Date Title
AU2609901A (en) Antimicrobial compositions and methods of use
AU7362301A (en) Bioadhesive compositions and methods of preparation and use
AU2002241611A1 (en) Orally-bioavailable formulations of fentanyl and congeners thereof
EP1291377B8 (fr) Compose de silicone et preparation cosmetique
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2001287023A1 (en) Plasma-derived-fibrin-based matrices and tissue
AU2001273074A1 (en) Combinations of ssri and estrogenic agents
AU2001295467A1 (en) Skin cosmetic formulations
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001269314A1 (en) Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
AU2406299A (en) Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
AU2002213422A1 (en) Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
AU2001222986A1 (en) Dehydroascorbic acid formulations and uses thereof
AU4647200A (en) Skin care compositions containing combination of skin care actives
AU2001288682A1 (en) Inhibition of cmv infection and dissemination
IL156411A0 (en) Hypoallergenic and non-irritant skin care formulations
AU4361600A (en) Skin care compositions containing combination of skin care actives
AU2002221273A1 (en) Delayed and sustained release formulations and method of use thereof
AU4647300A (en) Skin care compositions containing combination of skin care actives
AU2002230781A1 (en) Pharmaceutical uses and synthesis of benzobicyclooctanes
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU7522800A (en) Synergistic insecticidal formulations of pyridaben and strobilurins
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
AU2001268236A1 (en) Use of aicar and related compounds